Kindeva Drug Delivery Announces Collaboration with Monash University to Study Sustainable Propellants

Loughborough, U.K.—Kindeva Drug Delivery L.P. (Kindeva) has announced a collaboration with Monash University (Monash) to study alternative propellants for pressurized metered-dose inhalers (pMDIs) and develop more sustainable pMDI products. The collaboration will be jointly funded by Kindeva, Monash, and the Australian Research Council (ARC).

The collaboration with Monash will expand Kindeva’s research and development capabilities in the use of alternative propellants used in pressurized metered-dose inhalers (pMDIs). There is emerging interest within the industry to evaluate the potential use of propellants with lower Global Warming Potential (GWP) in order to develop more sustainable pMDI products. This partnership will leverage the extensive research facilities at Monash and bring together Monash’s expertise in measurement and inhalation device technologies with Kindeva’s innovative approach to bringing state-of-the-art inhalation drug products to market. A focal point of this opportunity is to gain a fundamental understanding of the atomization of pMDIs using low-GWP propellants in order to optimize drug delivery from these systems.

Kindeva, a leading global contract development and manufacturing organization (CDMO), has a long track-record of innovation in complex drug and combination products. The company has a history of over 65 years in innovating inhaled drug products, stretching back to the development of the first-ever pMDI. A proven leader in promoting sustainability in the industry, Kindeva led the transition from CFC- to HFA-based inhalers, developing the world’s first CFC-free pMDI and the world’s first CFC-free nasal pMDI.

“At Kindeva, we’re excited about the future of inhalation drug delivery,” said Aaron Mann, CEO of Kindeva. “A thoughtful, science-based development of low-GWP propellants is reminiscent of the industry’s transition from CFC-based to HFA-based inhalers—a transition that Kindeva helped to lead. Now, with better experimental processes and enhanced modelling capabilities, Kindeva and the industry are more equipped than ever to advance another propellant transition.”

“We are proud to be working with Monash, a leading academic innovator in the space,” added Mann. “Our partnership will accelerate the development of the more sustainable pMDI products that patients need.”

“We are excited to have the opportunity to work with Kindeva,” said Dr. Daniel Duke, the Lead Investigator on the project from Monash University’s Department of Mechanical and Aerospace Engineering. “Kindeva’s leadership in the development of CFC-free inhalers, combined with Monash’s unique optical, X-ray and simulation capabilities, affords us the best possible opportunity to address the challenge of reducing the environmental impact of pMDIs. This is a surprisingly complex scientific and engineering problem that requires innovative solutions.”